Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
IL-6: no change in healthy, metabolic disorders and arthritis, increased in cirrhosis and renal failure, decreased in PCOS + MS. IL-10: no change in healthy, IBD and metabolic disorders, increased in arthritis.
|
31060892 |
2020 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Finally, we showed a strong correlation between APRIL and IL-10 in the inflamed synovial tissue of inflammatory arthritis patients.
|
31258536 |
2019 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our previous work showed that under inflammatory condition MZ B-cells differentiated into IL-10 producing cells and contributed to the downregulation of collagen-induced arthritis, while follicular B-cells failed to do so.
|
31216428 |
2019 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Conversely, Sm infection did not affect the exacerbated arthritis in IL-10 KO mice, although IL-17A production was reduced by the helminth.
|
30194773 |
2019 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that TOV has significant anti-arthritic effects on collagen-induced arthritis in rats, which may be attributed to the inhibition of the levels of IL-1β, IL-6, IL-8, IL-17A, TNF-α, MMP-3 and MMP-9, and the increase of IL-10 in serum as well as down-regulation of the protein expression of COX-2 and iNOS in synovial tissues via suppressing the phosphorylation and degradation of IκB.
|
30831463 |
2019 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Administration of RvD5n-3 DPA to arthritic P. gingivalis-inoculated mice increased intestinal Il-10 expression, restored gut barrier function, and reduced joint inflammation.
|
31292292 |
2019 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Multitarget-based cotreatment with cilostazol and celecoxib synergistically suppresses collagen-induced arthritis in mice by enhancing interleukin-10 expression.
|
31170675 |
2019 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Butyrate inhibit collagen-induced arthritis via Treg/IL-10/Th17 axis.
|
30660077 |
2019 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to test the capacity of a newly developed fusion protein of interleukin 4 (IL-4) and IL-10 [IL4-10 fusion protein (FP)] to shift multiple pro-inflammatory pathways towards immune regulation, and to inhibit pro-inflammatory activity in arthritis models.
|
30307604 |
2019 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Interleukin-10 (IL-10) produced by butyrate-induced expanded T<sub>reg</sub> cells was critical, as treatment with butyrate did not affect inflammatory arthritis in IL-10-knockout mice.
|
30034392 |
2018 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our work demonstrated that EEC possessed the potential therapeutic effect against arthritis in rodents which was attributed to modulating proinflammatory cytokines TNF-α, IL-1β and anti-inflammatory factors IL-10.
|
29753098 |
2018 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
IL-17 deficiency ameliorated disease symptoms of inflammatory arthritis in IL-1RaKO mice by suppressing the frequency of plasma cells and antibody production while enhancing the frequency of IL-10-producing B cells.
|
29803636 |
2018 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, infusion of MDSCs from IL-10 KO mice failed to suppress inflammatory arthritis.
|
29491381 |
2018 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Increment in the level of IL-10 in the combination group could be positively correlated with the recovery of arthritis.
|
28326455 |
2017 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that anti-inflammatory cytokine IL-10 was a critical mediator for PGRN-mediated anti-inflammation in collagen-induced arthritis by using PGRN and IL-10 genetically modified mouse models.
|
28011648 |
2017 |
Arthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, administration of PF (5, 10 and 20 mg/kg/day) for 28 days markedly exhibited an anti-arthritic activity by offsetting the body weight loss, inhibiting the paw edema, reducing the arthritis scores and the indices of thymus and spleen, inhibiting the expression levels of TNF-α, IL-1β, IL-6, COX-2 and 5-LOX, and increasing the expression of IL-10, when compared with the respective control group in CFA-induced arthritis assay.
|
28352356 |
2017 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The results corroborate our previous findings, using the same fusion protein approach, in the collagen-induced arthritis model showing dramatic suppressive effects on Th1 and Th17 autoaggressive CD4 T cells and upregulated regulatory T cell activities with enhanced IL10 production.
|
28959261 |
2017 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Modeling the increase in mucosal and systemic T<sub>H</sub>17 immunity we observed in CD-SpA patients, colonization of interleukin-10-deficient or K/BxN mice with CD-SpA-derived <i>E. coli</i> lead to more severe colitis or inflammatory arthritis, respectively.
|
28179509 |
2017 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
DBA/1 mice doubly deficient in IL-4 and IL-10 were used to confirm that these two cytokines are important for the APL-induced attenuation of arthritis.
|
27837109 |
2016 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
APL-2, an altered peptide ligand derived from heat-shock protein 60, induces interleukin-10 in peripheral blood mononuclear cell derived from juvenile idiopathic arthritis patients and downregulates the inflammatory response in collagen-induced arthritis model.
|
24474501 |
2015 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our data identify a novel role for FoxO1 in regulating IL-10 secretion during classic activation and highlight the potential for therapeutic interventions for chronic inflammatory conditions, such as atherosclerosis, diabetes, inflammatory bowel disease, and arthritis.
|
25420919 |
2015 |
Arthritis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Individuals with IL-10 receptor mutations also experience cutaneous folliculitis and arthritis.
|
25004811 |
2014 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Pre-clinical Vac-PSG1a treatment suppressed the Th1- and Th17-type-specific responses, leading to an increase in splenic Treg cells as well as IL-10- and TGF-β-secreting cells, with the CIA symptoms being ameliorated.
|
25112392 |
2014 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The described products may represent useful research tools for the study of the anti-arthritic properties of TNF blockade and of IL10-based immunocytokines in syngeneic immunocompetent models of arthritis.
|
24289726 |
2013 |
Arthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice.
|
23166758 |
2012 |